ESR1 and breast carcinoma: It has been suggested that AR could be an emerging therapeutic target in breast cancer, especially tumors that are ER-negative, and scientific interest has been focused on the clinical significance of AR expression in ER-positive or triple-negative breast cancer [29,30,31].